March 14, 2013—The Health Resources and Services Administration (HRSA) is developing a comprehensive regulation for the entire 340B drug discount program that, among other provisions, would restate which patients may receive 340B-discounted medicines.
Office of Pharmacy Affairs (OPA) Director Cmdr. Krista Pedley disclosed the plan for an omnibus 340B rule during a March 12 meeting of drug manufacturer representatives in Baltimore.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)